Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $81.20 +1.87%
EPS Growth %: -96.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -96.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.53 million.
2017 revenue guidance increased by $20 million, to $145-155 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- Creatd files Form S-1 and reports Q1 2026 financial results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
